I’ll come back shortly to why I view the stock as a top blue-chip growth buy. First, I’d like to tell you about mid-cap Synthomer (LSE: SYNT), which has been one of the FTSE 250‘s top-performing stocks of the last 10 years.

On track

Synthomer, which released a trading update this morning, provided its investors with an average return of 28% a year over the 10 years ended 31 December. And this year, the shares are up 14% so far, despite a 2% pullback in early trading today.

A speciality chemicals firm, Synthomer is one of the world’s leading suppliers of aqueous polymers. It serves customers in a wide range of industries, its polymers ending up in products as diverse as industrial flooring and medical examination gloves.

In today’s update, management reported that overall group performance in the first quarter of the year had been in line with its expectations. And it said its “full-year 2019 outlook remains unchanged.”

Still very buyable

City analysts are forecasting annual earnings growth of 5%-6%. At a share price of 405p, the price-to-earnings (P/E) ratio is 11.8 based on forecasts for the current year, falling to 11.1 on next year’s forecasts.

Add to the earnings growth a forecast dividend yield of 3.4%, rising to 3.6%, and you’ve got implied annual returns in high single-digits. The P/E is currently modest by the company’s historical standards, so there’s potential for higher returns, if the market decides to revert to a higher rating. The stock remains very buyable at the current price, I’d say.

Transformation

Rolls-Royce has come through a very difficult few years. Some of the challenges it faced were outside its control, but some can be laid at the door of previous management over a number of years.

When a company as big as Rolls-Royce has to undergo a major restructuring of its businesses, and change in its corporate culture, it takes time. I admire current chief executive Warren East, and the way he’s gone about the transformation, and I see similarities with Tesco boss Dave Lewis and the turnaround of the supermarket giant. Both men were able to hail a breakthrough year in delivering their latest annual results.

Top growth bargain

As you might expect for a company forecast to deliver earnings growth in excess of 50% this year and next, Rolls-Royce’s forward P/Es are significantly higher than Synthomer’s. At a share price of 915p, the aerospace group’s P/Es are 36 and 24.

However, due to the strength of the earnings growth, the price-to-earnings growth (PEG) ratio is highly attractive. Ratios of 0.6 for this year and 0.5 for next, are both deep on the good value side of the PEG fair value marker of 1.

For this reason, I see Rolls-Royce as a top FTSE 100 growth bargain. Meanwhile, its running dividend yield of 1.3% is only modest, but the payout can be expected to rise strongly in the coming years on the back of the anticipated impressive earnings growth.

The post Why I think the Rolls-Royce share price is a FTSE 100 growth bargain appeared first on The Twelfth Magpie.

More reading

• After huge new nuclear deals, are Rolls-Royce’s sub-£15 shares set to power higher?
• Here’s how much I think Rolls-Royce shares will be worth by the end of 2027
• Could small modular reactors take Rolls-Royce shares to the next level?
• Is now the perfect time to buy Rolls-Royce, Babcock and BAE System shares?
• The SpaceX frenzy is over – is it time to look at Rolls-Royce shares again?

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Synthomer and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

However, after its decline, Next now seems to me to offer a relatively appealing valuation. Could it be worth buying alongside another stock which reported an encouraging update on Tuesday?

Strong performance

The company in question is supplier of aqueous polymers Synthomer (LSE: SYNT). It released a third quarter update which confirmed that it is on track to meet guidance for the full year. Its performance in Europe and North America was solid, while growth in the Asia and Rest of World segment was in line with expectations.

It believes that its product and geographic diversity make it well-placed to overcome the challenging macroeconomic and political environment which is being experienced across the globe at the present time. It has also announced a change to its organisational structure, with three new business groups set to be created from January. The company believes that the new structure will enable it to better leverage its global product portfolio, as well as exploit its R&D capabilities.

Looking ahead, Synthomer is forecast to post a rise in earnings of 7% in the current year, followed by further growth of 10% next year. With the stock trading on a price-to-earnings growth (PEG) ratio of around 1.8, it seems to offer good value for money and I feel it may post improving share price performance over the coming years.

Sound strategy

Meanwhile Next may also be able to deliver improving share price performance. The company is seeking to adapt to changing consumer tastes through a strategy that will see it focusing increasingly on leisure experiences as consumer spending gradually shifts from retail to leisure areas. As such, it is seeking to broaden the appeal of its stores to include offerings such as cafes. This could draw people into stores and lead to higher overall sales.

The company is also seeking to adapt to an increasingly online world. Shopping habits are changing, so the business is investing heavily in its website. It is also seeking to leverage its stores when it comes to online sales, with store-to-store transfers and click-and-collect becoming increasingly popular among customers.

With Next now having a price-to-earnings (P/E) ratio of around 13.8, it seems to offer good value for money given its track record of growth in difficult economic periods. Its relatively high degree of customer loyalty and its adaptability may allow it to outperform a number of its sector peers during what is a tough period for the wider UK retail sector. As such, I think now could be the right time to buy it after its recent share price decline.

The post Is Next’s share price a steal after its 15% fall? appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Peter Stephens has no position in any of the shares mentioned. The Motley Fool UK has recommended Synthomer. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

You’re already a customer

You probably use at least one Victrex (LSE: VCT) product without realising it. This chemicals group was spun out of ICI in 1993, since when sales have grown from £30m to more than £290m.

The company now makes speciality polymers such as plastics and resins for a wide range of industrial customers. For example, more than 1bn smartphones and 200m cars contain Victrex products.

Still growing fast

Today’s half-year results show that impressive growth is continuing. Group sales rose by 21% to 2,256 tonnes during the six months to 31 March, driving a 27% increase in revenue to £166.6m.

Profits were up too. The group’s pre-tax profit climbed 26% to £63.3m, compared to the same period last year. Earnings per share rose by 39% to 64.7p and shareholders will get a 10% pay rise as the interim dividend will be increased to 13.4p per share.

All of this sounds positive to me. So why did the shares fall by nearly 5% shortly after the markets opened?

This could be why

In today’s results, chief executive Jakob Sigurdsson warned that favourable exchange rate movements are expected to boost profits by £10m this year. This tailwind is likely to reverse next year, slowing earnings growth.

Half-year earnings also received a one-off boost from the UK’s new Patent Box legislation, which has reduced the effective tax rates for innovative firms such as Victrex.

I’d still buy

I don’t see these factors as a serious concern. Exchange rates usually balance out over the long term, and Victrex remains a fantastically profitable business.

The group’s operating margin was 38% during the first half, which is outstanding. Net cash of £91.8m was also ahead of the same point last year, despite the firm paying out £94m of dividends over the last 12 months.

Analysts expect another special dividend in 2018 and are forecasting a total payout of 121.9p per share, giving the stock a forecast yield of 4.5%.

Although the shares look pricey on 20 times 2018 forecast earnings, I believe the quality and profitability of this business justifies the price tag. I’d keep buying and would plan to hold this stock forever.

Another FTSE 250 contender?

Another potential choice from the chemicals sector is Synthomer (LSE: SYNT). This company also supplies specialist polymers, but serves different markets, including floor coverings, medical latex and various protective coatings.

The Synthomer share price has risen by 162% over the last five years, highlighting the long-term growth potential of this business.

A step change?

The group expanded its production capacity significantly last year and also made bolt-on acquisitions that should help to add new business in key sectors such as packaging. Analysts expect the group’s adjusted earnings to rise by 6% to 32.4p per share this year, putting the stock on a forecast P/E of 15.4, with a prospective yield of 2.6%.

In my view this looks a fair valuation for a long-term growth business. I’d continue to rate the shares as a buy at this level.

The post 2 FTSE 250 dividend growth stocks I’d buy and hold forever appeared first on The Twelfth Magpie.

More reading

• With a 9.5% yield, this FTSE 250 dividend share could climb up to 40%!
• Could a portfolio of dividend shares turn £10,000 into £20,097 in 10 years?
• This dividend stock yields 9.8% and is potentially 44.3% undervalued!
• 5 UK dividend shares with 7%+ yields
• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Victrex. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Reporting on Thursday was a FTSE 250 dividend growth stock which seems to offer a strong income future. However, it may not be the most appealing dividend play in the mid-cap index at the present time.

Solid performance

Releasing a first quarter trading update on Thursday was aqueous polymer specialist Synthomer (LSE: SYNT). Trading during the period has been relatively consistent, with its Europe and North America segment delivering higher volumes than in the comparative period. This was largely due to the positive impact of the Speciality Additives and Pischelsdorf SBR latex acquisitions.

Similarly, the company’s performance in Asia and the Rest of World segment was in line with expectations. Nitrile latex volumes were marginally higher than in the weaker comparative period when customer spending was hurt by a volatile raw material environment. This has helped the business to remain on track to meet its guidance for the full year.

With Synthomer forecast to deliver earnings growth of 5% in the current year and a further 10% next year, it seems to be performing well. This should enable it to raise dividends per share by around 7% per annum during the next two years, which puts it on a forward dividend yield of 2.8%. Since dividends are covered 2.5 times by profit, they could rise rapidly over the medium term and improve the company’s income outlook.

Low valuation

While Synthomer appears to offer an upbeat dividend future, fellow FTSE 250-listed company Crest Nicholson (LSE: CRST) could offer an even more compelling income investment outlook. The housebuilder has a dividend yield of over 7% at the present time, with further dividend growth forecast over the next two years.

The company is expected to report a rise in earnings of 6% this year, followed by additional growth of 12% in the 2019 financial year. These figures should enable dividend growth of over 10% per annum during the same time period, which could lead to a dividend yield of over 8% next year.

Clearly, the housebuilding sector faces an uncertain future and Crest Nicholson’s share price could prove to be highly volatile. However, with the company’s dividend being covered twice by profit and it trading on a price-to-earnings (P/E) ratio of around 8, it seems to offer a wide margin of safety.

Therefore, for long-term income investors who are comfortable with the potential for above-average volatility in the short term, it could prove to be a sound risk/reward opportunity at the present time. Its low valuation plus high dividend growth prospects could mean it is able to justify a higher share price in future years.

The post This FTSE 250 dividend growth stock isn’t the first share I’d buy despite today’s positive news appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Peter Stephens owns shares of Crest Nicholson. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

That’s why Legal & General (LSE: LGEN) could be a shrewd investment. It has an excellent track record of raising dividends, and it appears set to continue this trend in future. However, it’s not the only stock which could be worth buying today for its dividend growth potential.

Improving performance

Reporting on Monday was speciality chemical company Synthomer (LSE: SYNT). Its third quarter trading update showed that it is performing in line with expectations, which means it is on target to meet its full-year forecasts.

In Europe and North America, third quarter reported volumes and unit margins were in line with the same period of last year. This was despite some weakness in Dispersions for Construction and Coatings applications, which were offset by strong performance in Latex for the Paper and Foam markets.

In Asia and the Rest of the World, the company’s performance was also in line with expectations. Volumes were flat versus the same period of last year, with the underlying market for Nitriles continuing to grow at more than 10%. This should help the business to deliver sustainable growth while it also seeks to evaluate potential acquisition opportunities.

Dividend potential

In the last five years, dividends paid by Synthomer have increased from 5.5p per share to just under 12p per share. This is an increase of around 115%, and yet the company’s dividend coverage ratio remains highly sustainable. It stands at 2.5, which suggests that there could be further dividend growth ahead over the medium term.

Similarly, Legal & General has increased dividends per share by 100% over the last five years. It has a dividend coverage ratio of 1.6 times at the present time, and this indicates that more dividend growth could be ahead. Such a large level of headroom when making payouts to shareholders for both companies could mean that they are able to offer dividend growth rates which exceed inflation in 2018 and beyond.

Valuations

As well as high dividend growth prospects, both companies appear to offer wide margins of safety at the present time. Legal & General has a price-to-earnings (P/E) ratio of 10.7, while Synthomer’s P/E ratio of 17 also suggests that there could be upside potential ahead. Both stocks are expected to deliver positive earnings growth this year, which could provide a further boost to their dividend growth rates.

Certainly, neither stock may be able to double their dividends in the next five years as they did in the last half-decade. But they should be able to beat inflation, which could make them worthwhile buys for the long term.

The post Legal & General Group plc isn’t the only dividend growth king I’d buy today appeared first on The Twelfth Magpie.

More reading

• How much would I need in a Stocks and Shares ISA to target £19,036 a year in second income?
• Here’s why I bought this 7.6%-yielding FTSE 100 dividend stock instead of saving in a Cash ISA
• How much would you need in a Stocks and Shares ISA to match the State Pension?
• Here’s a quick and easy way to start earning passive income this summer with a spare £1,000
• How much would I need to invest in these FTSE 100 dividend gems for a £29,061 ISA passive income?

Peter Stephens owns shares in Legal & General. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

And diversified subprime lender Non-Standard Finance (LSE: NSF) is also taking its opportunity by accelerating growth in the doorstep lending division by hiring more agents at a rapid clip. Indeed in H1 results released this morning, the company’s management went out of its way to say: “The restructuring of a major competitor has presented us with a significant opportunity to grow.” No prizes for guessing who that competitor is…

On top of growing its doorstep lending business, which is already the third largest in the UK, the company’s secured loan- and branch-based lending divisions also grew nicely during the six months to June. All together, underlying revenue rose 16% year-on-year (y/y) to £52m and underlying pre-tax profits jumped 26% to £5.4m. The relatively young company is still loss-making at a statutory level due to expansion but these losses are narrowing as the benefits of increased scale roll in.

In addition to this very good set of interim results the company also announced the £53m acquisition of guaranteed loan provider George Banco that will make NSF the clear number two player in this market. The acquisition will be earnings accretive in 2018, which isn’t surprising as George Blanco recorded £9.3m in revenue and £4.1m in EBITDA over the past year.

NSF has been given what could be a once-in-a-lifetime opportunity to gain and hold market share at the expense of Provident. So far it appears management is taking advantage of this which, together with growth in its other business lines, rising dividend payments, and an attractive valuation of 13.6 times forward earnings, makes it worth taking a closer look at.

A safer option 

A more established growth stock that’s caught my eye is speciality chemical producer Sythomer (LSE: SYNT). The company works closely with clients to design everything from synthetic rubber for medical gloves to binding for magazines and has grown at a respectable clip in recent years through organic expansion and small acquisitions.

In 2016, this twin-pronged growth strategy led to sales rising 10.8% y/y, in constant currency terms, and a full 20.2% at actual exchange rates. This boost from the weak pound could be a one-off, but the growth of the underlying business through very good trading in Europe and Asia should be welcomed.

Aside from diversified revenue streams and geographic markets, I’m also attracted to Synthomer’s solid profitability. Last year’s operating profits of £130.2m represent margins of 12.4% that were impressively resilient given rising raw material prices in Europe.

With a good business model of exploiting its expertise in niche sectors, high growth potential, and a reasonable valuation of 16.8 times forward earnings, Synthomer is certainly one company I’ll continue following closely.

The post Provident Financial plc’s problems are a huge opportunity for this growth stock appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Synthomer’s results were given a boost last year by the weaker pound. But the firm’s performance was impressive without this. Volumes rose by 9%, and underlying pre-tax profit at constant exchange rates rose by 16.4%.

The firm has announced a modest-sized acquisition today which should provide a further boost to earnings. In this article I’ll consider the case for buying Synthomer and look at another mid-cap growth opportunity.

This stock could outperform again

Synthomer makes specialist chemicals used in a wide range of manufacturing applications. This diversity helps to insulate the group from the sector-specific problems we’ve seen at companies that depend on the oil industry, for example.

Net debt of £150.3m is very low relative to the group’s profits. Shareholders benefit from strong cash generation. The dividend was increased by 31.6% to 11.3p per share last year. I estimate this payment should be covered comfortably by free cash flow.

As you’d expect from a high-quality growth stock, Synthomer shares aren’t cheap. They currently trade on a 2017 forecast P/E of 16.5, with a prospective yield of 2.4%. But it’s worth remembering that earnings forecasts for this firm were increased nearly every month in 2016.

If Synthomer continues to outperform expectations in 2017, the firm’s current share price could look cheap by the end of the year. I’d be happy to buy this stock at current levels.

The pick of the bunch?

Home and motor insurance group Hastings Group (LSE: HSTG) only floated on the London market in October 2015, but it’s already made a strong impression. The firm’s shares have risen by 40% so far, but the stock doesn’t look expensive to me.

The total value of premiums written last year rose by 25% to £768.0m. Market share for private car insurance increased from 5.8% to 6.5%. Adjusted operating profit would have risen by 21% to £152.1m, if it wasn’t for a £20m one-off charge following the so-called Ogden rate change.

This legal change will mean that Hastings (like all insurers) has to pay out more in compensation payments to allow for lower interest rates. But the firm doesn’t expect the change to have a material impact on 2017 profits, as insurance rates will be adjusted to reflect the higher costs. Nor should this change result in an increase in borrowing — Hastings’ multiple of net debt-to-adjusted operating profit fell from 2.1 times to 1.9 times last year, despite the impact of the Ogden change.

Hastings earnings per share are expected to rise by a 65% to 19.6p this year. This puts the stock on a forecast P/E of 12, with a prospective yield of 4.8%. In my view this is an undemanding valuation, given that the group’s strong record of growth.

I’d be happy to add Hastings to my portfolio at current levels for both income and growth.

The post Two FTSE 250 growth stocks you may want to buy in March appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Roland Head has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Improving performance

During the first three quarters of the year, Synthomer experienced positive trends in its European and North American divisions. They continued in Q4 and the company saw better than expected results across all business segments. It also benefitted from further improvements within its refreshed strategy, which has focused on new product initiatives, greater efficiency, a strengthened procurement function and greater investment in business development.

Strong performance was also recorded in Asia and the Rest of the World. Those regions performed modestly ahead of expectations in the final quarter, with the competitive dynamics in the Asian Nitrile business continuing to evolve. This follows the introduction of additional industry capacity in the second half.

Similarly, the integration and trading performance of Hexagon PAC has progressed in line with expectations and is on target to meet expectations for 2016. Taken together, the overall performance of the company is expected to have beaten previous guidance for 2016.

Further growth potential

Of course, the chemical industry isn’t a particularly consistent sector when it comes to profit growth. In the last five years, Synthomer has recorded falls in its bottom line in two of those years. It’s a similar story with sector peer Johnson Matthey (LSE: JMAT). Its bottom line has fluctuated significantly and this means it has lacked overall growth during the period.

But looking ahead, both stocks are expected to experience upbeat performance. In the case of Synthomer, its earnings are forecast to rise by 4% in 2017, followed by 7% growth in 2018. Alongside a price-to-earnings (P/E) ratio of 16.5, this indicates further share price growth could be on the horizon. However, its sector peer offers superior value for money as well as better growth potential. Johnson Matthey is expected to record a rise in its earnings of 7% in each of the next two financial years. With a P/E ratio of 14.4, this indicates that it offers greater upside than its industry peer.

Of course, Synthomer could prove to be a sound long-term buy. As today’s update showed it has improved its business model and is benefitting from better than expected performance in some of its key markets. This trend is expected to continue over the course of 2017, so it may yet beat its forecasts. However, since Johnson Matthey has a lower valuation, a wider margin of safety and superior growth prospects, it appears to be the more enticing buy of the two chemicals companies at the present time.

The post Is 15% riser Synthomer plc a buy after beating expectations? appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Shares in Synthomer (LSE: SYNT) rallied today after announcing the acquisition of Hexion Performance Adhesives & Coatings. The £156m purchase of US-based Hexion will be completed in the summer subject to regulatory approval.

Shares in FTSE 250 listed Synthomer have performed well lately gaining around 20% over the past month. Brokers in The City expect a tiny 1% rise in earnings this year, with 21.77p per share expected compared to 21.50p per share last year.

The shares go ex-dividend on 02 June 2016 with the final payment of 5.4p payable on 04 July 2016. Dividends are forecast at 9.53p and 9.59p for 2016 and 2017 respectively, offering a prospective yield of around 2.9% for the next two years.

Synthomer currently trades on 15 times forecast earnings for the current year, with the P/E ratio forecast to stay at 15 for the year ending 31 December 2017.

At current levels, the shares seem fairly priced, and I do not see any compelling reason to buy. Investors should stay on the sidelines for now.

Good value

Shire (LSE: SHP) also moved higher today, with its shares reaching 3846p by lunchtime. The FTSE 100 listed drugs company is recovering from a share price slide that started in August 2015 when it reached a peak of 5870p.

City analysts expect earnings to fall by 32% to 264.15p per share for the year ending 31 December 2015, followed by a rise of 12% to 294.90p this year, and a further rise of 15% to 339.22p in 2017.

Dividends are forecast at 17.10p, 20.78p and 24.74 for 2015, 2016 and 2017, respectively, offering prospective yields of 0.5%, 0.6% and 0.7% for the next three years. The shares currently trade on a forecast P/E ratio of 14 for fiscal 2015, falling to 12.5 for 2016, and 10.8 in 2017.

At present levels, the shares offer good value given the relatively low P/E ratio. Investors should BUY for capital growth.

Not now

Mid-cap miner Evraz (LSE: EVR) also enjoyed early gains with shares reaching 93.2p in early trading. The shares have rallied recently gaining 47% over the past month, but are still down 54% over the past year.

Full year results revealed a narrowing of pre-tax losses from $1084m to $707m, whilst revenue dropped from $13.1bn to $8.8bn, and losses per share narrowed from 78 cents to 45 cents.

Consensus forecasts predict earnings to remain flat at around 1.9p per share this year, followed by a leap of 210% next year. Dividends are forecast at 0.86p and 1.16p for 2016 and 2017, offering a prospective yield of around 1.0% and 1.3& for the next two years.

Evraz currently trades on 93 times forecast earnings for the current year, falling to 23 for the year ending 31 December 2017.

At present levels, the shares look expensive given the relatively high earnings multiple and I think investors should avoid Evraz for now.

What Next?

I believe Shire looks undervalued and represents a bargain for value investors. However, I don’t think Synthomer offers any significant upside potential or meaningful dividend income, and Evraz looks overvalued at the present time.

The post 3 Big Winners: Shire plc, Synthomer plc & Evraz plc. Should You Buy Or Sell Today? appeared first on The Twelfth Magpie.

More reading

• £5,000 invested in this red-hot UK growth stock 3 months ago is now worth…

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Clearly, a weak Eurozone has not been good news for the company and, with the Euro depreciating considerably as a result of a looser monetary policy being employed by the ECB, Synthomer’s financial performance has been held back somewhat by currency headwinds. However, the underlying performance of the business is strong, with its construction and coatings, functional polymers and foam markets all delivering impressive performance.

Looking ahead, Synthomer has a bright outlook. For example, in the current year it is forecast to increase its bottom line by 4%, while in 2016 its net profit is set to rise by as much as 10%. And, even though its shares have risen by a whopping 43% since the turn of the year, they still trade on a respectable price to earnings (P/E) ratio of 16.6. This means that Synthomer trades on a price to earnings growth (PEG) ratio of just 1.6, which indicates that its share price could continue to move higher over the medium term.

In fact, Synthomer looks set to continue to outperform its chemicals sector peer, Johnson Matthey (LSE: JMAT). It has seen its share price fall by 14% since the turn of the year and, even so, it still trades on a relatively high valuation. For example, Johnson Matthey has a P/E ratio of 15.8 and, when its growth prospects are taken into account, this rating seems to be rather high.

For example, Johnson Matthey is expected to post a rise in its bottom line of just 2% this year, followed by 7% next year. This puts it on a PEG ratio of 2, which indicates that Synthomer has greater potential to deliver capital gains. And, with Synthomer having a yield of 2.9% versus 2.5% for Johnson Matthey, it appears to be a more promising income stock, too.

Clearly, there are other stocks in the FTSE 350 that offer even more potential growth and income performance than Synthomer. That’s at least partly because the chemicals sector is relatively popular among investors at the present time (as highlighted by the performance of Synthomer in 2015). However, the banking sector enjoys far less appeal among investors right now, with HSBC’s (LSE: HSBA) P/E ratio of just 11 indicating that it has tremendous scope for an upward rerating over the medium to long term.

Furthermore, HSBC yields almost twice that of Synthomer, with its yield standing at 5.7%. And, with HSBC expected to post earnings growth of 18% this year, its PEG ratio of 0.6 indicates that its shares could turn the tables on poor performance during 2015 that has seen them decline by 5% year-to-date.

So, while Synthomer may be a more appealing investment prospect than sector peer, Johnson Matthey, HSBC remains the preferred option for long term investors.

The post Should You Buy Synthomer PLC Instead Of HSBC Holdings plc And Johnson Matthey PLC? appeared first on The Twelfth Magpie.

More reading

• Up 250%! Here’s why I bought HSBC shares over SpaceX stock
• How much might £19,999 in a Stocks & Shares ISA be worth by 2036?
• Could a Stocks and Shares ISA eventually replace the State Pension?
• 2 bank shares I like better than Lloyds today
• How much do I need to invest in HSBC shares to target £5,986 a year in second income?

Peter Stephens owns shares of HSBC Holdings. The Motley Fool UK has recommended HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.